reports
- ING Helpdesk
Benelux Morning Notes
AEGON: Uneventful results, US weaker, underlying OCG in line / Air France-KLM: Productivity gains starting to filter through / Arcadis: Weak revenues and EBITA, but strong NWC / Ascencio: Results in line, no concerns on Carrefour Belgium exposure / Azelis: Persisting softness in 4Q25, continued focus on costs and cash / BAM Group: Solid 2H25 results, 2026 outlook in line / Belgian telecoms: Telenet improved net adds, to relist as part of Ziggo in 2027, Liberty to sell half of its 66% Wyre stake ...
PROX PROXIMUS SA DE DROIT PUBLIC
KPN ROYAL KPN NV
BAMNB KONINKLIJKE BAM GROEP NV
AF AIR FRANCE-KLM SA
GIMB GIMV NV
ARCAD ARCADIS NV
ASC ASCENCIO SCA
VGP VGP NV
KIN KINEPOLIS GROUP NV
OBEL ORANGE BELGIUM SA
BESI BE SEMICONDUCTOR INDUSTRIES N.V.
AZE AZELIS GROUP NV
AGN AEGON N.V.
MICC MAGNUM ICE CREAM COMPANY N.V. (THE)
- Guy Sips
- Hilde Van Boxstael
- Kristof Samoy
- Mathijs Geerts Danau
- Michiel Declercq
- Thibault Leneeuw
- Thomas Couvreur
- Wim Hoste
- Wim Lewi
- Lynn Hautekeete
Ascencio 1Q26 trading update: No mention of Carrefour exit in report
Ascencio reports EPRA earnings in line with our expectations. Rental income came in slightly below due to a 60 bps increase in vacancy at an unknown Walloon site requiring repositioning. In its report, Ascencio hints at further acquisitions as it feels comfortable at its 41,4% debt ratio (before dividend payment, incl. € 22,8m acquisition). There is no mention of Carrefour in its trading update. Carrefour has 4,4% of Ascencio's contractual rents. The assets are on average 22,5% overrented. Hence...
- Mathijs Geerts Danau
Hyloris Valacyclovir oral suspension is delayed
Hyloris provided an update regarding the review of valacyclovir for oral suspension which had a PDUFA target action date of 12 October 2025. It appears that the FDA identified significant inspection observations at the third party manufacturing plant in Greece. The manufacturer confirmed that it is actively implementing its remediation plans. Currently, Hyloris believes that resolution of the manufacturing situation is required to obtain an FDA product approval and is working on a solution. We r...
Interim statement at 31/12/2025
Interim statement at 31/12/2025 Growth of the property portfolio Retail Park Horizon Provence (France) €22,8 million EURINVESTMENT AMOUNT Results for the 1st quarter for the financial year 2025/2026 €1.39EPRA EARNINGS PER SHARE€68.56INTRINSIC VALUE PER SHARE (EPRA NTA)StabilityOF THE FAIR VALUE OF THE PORTFOLIO96.6%EPRA OCCUPANCY RATE41.4%EPRA DEBT RATIO (EPRA LTV) ESG implementation: 90 new charging stations installed in France Attachment
Déclaration intermédiaire au 31/12/2025
Déclaration intermédiaire au 31/12/2025 Croissance du portefeuille immobilier Retail Park Horizon Provence (France) 22,8 millions EURMONTANT DE L’INVESTISSEMENT Résultats du 1er trimestre de l’exercice 2025/2026 1,39 EURRESULTAT EPRA PAR ACTION68,56 EURVALEUR INTRINSEQUE PAR ACTION (EPRA NTA)StabilitéDE LA JUSTE VALEUR DU PORTEFEUILLE96,6%TAUX D’OCCUPATION EPRA41,4%RATIO D’ENDETTEMENT EPRA (EPRA LTV) Réalisation ESG : 90 nouvelles bornes de recharge installées en France Pièce jointe
Tussentijdse verklaring op 31/12/2025
Tussentijdse verklaring op 31/12/2025 Groei van de vastgoedportfeuille Retail Park Horizon Provence (Frankrijk) 22,8 miljoen EURBEDRAG VAN DE INVESTERING Resultaten van het 1ste kwartaal van het boekjaar 2025/2026 €1.39EPRA EARNINGS PER AANDEEL€68.56NETTOACTIEFWAARDE PER AANDEEL (EPRA NTA)StabieleREËLE WAARDE VAN DE PORTEFEUILLE96.6%EPRA BEZETTINGSGRAAD41.4%EPRA SCHULDRATIO (EPRA LTV) ESG-realisatie: 90 nieuwe laadpalen geïnstalleerd in Frankrijk Bijlage
- Mathijs Geerts Danau
Inventiva FIRST LOOK: preliminary FY25 results hold no surprises
Inventiva reported preliminary FY25 results which hold no surprises, and confirmed its cash-runway guidance, which following the € 149m capital raise announced in November 2025, extends the company's runway to middle of 1Q27. This provides funding beyond the expected topline results from the phase 3 (NATiV3) trial of lanifibranor in MASH which are expected in 2H26. We reiterate our Buy rating and € 7 TP.
- Guy Sips
- Mathijs Geerts Danau
- Wim Hoste
Inventiva reports preliminary 2025¹ fiscal year financial results
Inventiva reports preliminary 2025¹ fiscal year financial results Cash and cash equivalents at €99.3 million, and €131.6 million in short-term deposits2 as of December 31, 2025Revenues of €4.5 million in 2025Completed a U.S. registered public offering for gross proceeds of approximately $172.5 million (€149 million3)Cash runway expected until the middle of the first quarter of 20274 Daix (France), New York City (New York, United States), February 17, 2026 – (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the developmen...
Inventiva publie ses résultats financiers préliminaires pour l’exercic...
Inventiva publie ses résultats financiers préliminaires pour l’exercice 2025¹ Trésorerie et équivalents de trésorerie à 99,3 millions d’euros, et 131,6 millions d’euros en dépôts à court terme2 au 31 décembre 2025Chiffre d’affaires de 4,5 millions d’euros en 2025Réalisation d’une offre au public aux États-Unis pour un produit brut total d’environ 172,5 millions de dollars (149 millions d’euros)3Horizon de trésorerie prévue jusqu’au milieu du premier trimestre 20274 Daix (France), New York City (New York, Etats-Unis), le 17 février 2026 – (Euronext Paris and Nasdaq :IVA) (« Inventiva » ou ...
Disclosure of transparency notification
Disclosure of transparency notification Article 14, paragraph 1 of the law of 2 May 2007 on disclosure of major shareholdings Ascencio has received a transparency declaration from Carl, Eric and John Mestdagh as well as the controlled companies informing her that they now jointly hold 787,418 voting rights in the Company. They jointly declare a 11.94% shareholding. Crossing of the 5% threshold upwards by Carl Mestdagh and CMHC SRL. Attachment
Publication relative à une notification de transparence
Publication relative à une notification de transparence Article 14, Alinéa 1 de la loi du 2 mai 2007 relative à la publicité des participations importantes Ascencio a reçu une notification de transparence de la part de Carl, Eric et John Mestdagh ainsi que les sociétés liées l’informant qu’ils détiennent désormais conjointement 787.418 droits de vote de la Société. Ils déclarent de concert un actionnariat à 11,94%. Franchissement du seuil de 5% à la hausse par Carl Mestdagh et CMHC SRL. Pièce jointe
Openbaarmaking over een transparantieverklaring
Openbaarmaking over een transparantieverklaring Artikel 4,1E lid van de Wet van 2 mei 2007 op de openbaarmaking van belangrijke deelnemingen Ascencio heeft een transparantieverklaring van Carl, Eric en John Mestdagh en de verbonden ondernemingen die hem medelen dat zij nu gezamenlijk 787.418 stemrechten van de Vennootschap bezitten. Ze verklaren gezamenlijk een aandelenbezit van 11,94%. Overschrijding van de drempel van 5% naar boven door Carl Mestdagh en CMHC SRL. Bijlage
- Guy Sips
- Jacob Mekhael
- Kristof Samoy
- Livio Luyten
- Lynn Hautekeete
- Michiel Declercq
- Thibault Leneeuw
- Thomas Couvreur
- Wim Hoste
- Wim Lewi
Dynamic Top Pick List Update February 2026: Removing ASMi; Adding UCB
After today's changes (ASMi out, UCB in), we maintain a balanced approach in our Dynamic Top Pick List, with a particular emphasis on value stocks that have been overlooked. Our defensive holdings are overweight, including real estate, which stands to benefit from lower interest rates. We remove ASMi from our Dynamic Top Pick List as the recent share price performance has driven the valuation meaningfully ahead of fundamentals. Since early December, FY27 diluted EPS expectations have risen by a...
EVS EVS BROADCAST EQUIPMENT SA
UCB UCB S.A.
DIE D'IETEREN SA
SOF SOFINA SA
IBAB ION BEAM APPLICATIONS SA
ROYAL VOPAK NV
AED AEDIFICA SA
CSM CORBION NV
ABI ANHEUSER-BUSCH INBEV SA/NV
ARGX ARGEN-X SE
WDP WAREHOUSES DE PAUW SCA
AZE AZELIS GROUP NV
DEME DEME GROUP NV
SHUR SHURGARD SELF STORAGE LIMITED
Inventiva to Present at the Guggenheim Emerging Outlook: Biotech Summi...
Inventiva to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 Daix (France), New York (United States), February 4, 2025 – (Euronext Paris and NASDAQ: ) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced that CEO Andrew Obenshain has been invited to participate in a fireside chat at the upcoming Guggenheim Emerging Outlook: Biotech Summit 2026. The conference is being held February 11-12, 2026 at the Lotte New Yor...
Inventiva présentera au Guggenheim Emerging Outlook : Biotech Summit 2...
Inventiva présentera au Guggenheim Emerging Outlook : Biotech Summit 2026 Daix (France), New York (États-Unis), le 4 février 2026 – Inventiva (Euronext Paris et Nasdaq : IVA) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement de thérapies orales pour le traitement de la stéatohépatite associée à un dysfonctionnement métabolique (« MASH »), a annoncé aujourd’hui que son Directeur général, Andrew Obenshain, a été invité à participer à un « fireside chat » lors du prochain Guggenheim Emerging Outlook: Biotech Summit 2026. La conférence se tiendra le...
- Jean-François Granjon
- Louis Boujard
- CFA
SESGL SES SA FDR (CLASS A)
BVI BUREAU VERITAS SA
ITRK INTERTEK GROUP PLC
NOEJ NORMA GROUP SE
XIOR XIOR STUDENT HOUSING N.V.
KRN KRONES AG
ATS AT & S AUSTRIA TECHNOLOGIE & SYSTEMTECHNIK AKTIENGESELLSCHAFT
WAF SILTRONIC AG
CSM CORBION NV
WAVE WAVESTONE SA
ERF EUROFINS SCIENTIFIC SOCIETE EUROPEENNE
ZGN ERMENEGILDO ZEGNA NV
LHYFE LHYFE S.A.
VT5 VT5 ACQUISITION COMPANY AG
SGSN SGS SA
4X0 STEYR MOTORS AG
- Jean-François Granjon
- Louis Boujard
- CFA
SESGL SES SA FDR (CLASS A)
BVI BUREAU VERITAS SA
ITRK INTERTEK GROUP PLC
NOEJ NORMA GROUP SE
XIOR XIOR STUDENT HOUSING N.V.
KRN KRONES AG
ATS AT & S AUSTRIA TECHNOLOGIE & SYSTEMTECHNIK AKTIENGESELLSCHAFT
WAF SILTRONIC AG
CSM CORBION NV
WAVE WAVESTONE SA
ERF EUROFINS SCIENTIFIC SOCIETE EUROPEENNE
ZGN ERMENEGILDO ZEGNA NV
LHYFE LHYFE S.A.
VT5 VT5 ACQUISITION COMPANY AG
SGSN SGS SA
4X0 STEYR MOTORS AG
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.